Alexion Pharmaceuticals (ALXN) Tops Q4 EPS by 7c; Issues FY12 EPS, Revs Outlook
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Financial Fact:
Research and development: 179.31M
Today's EPS Names:
FWDI, GO, BATL, More
Financial Fact:
Research and development: 179.31M
Today's EPS Names:
FWDI, GO, BATL, More
Join SI Premium – FREE
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q4 EPS of $0.41, $0.07 better than the analyst estimate of $0.34. Revenue for the quarter came in at $227.6 million versus the consensus estimate of $220.75 million.
Alexion Pharmaceuticals, Inc. sees FY2012 EPS of $1.60-$1.70, versus the consensus of $1.67. Alexion Pharmaceuticals, Inc. sees FY2012 revenue of $1.04-$1.07 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.
Alexion Pharmaceuticals, Inc. sees FY2012 EPS of $1.60-$1.70, versus the consensus of $1.67. Alexion Pharmaceuticals, Inc. sees FY2012 revenue of $1.04-$1.07 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Alexion Pharmaceuticals, Inc. (ALXN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta upgraded as AI security opportunity boosts outlook
- Toast Inc. (TOST) PT Raised to $39 at Truist Securities
- Goldman Sachs expects July core PCE to rise 0.23%
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
